Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target [Yahoo! Finance]
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: Yahoo! Finance
Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target On March 12, 2026, Craig-Hallum reaffirmed its Buy rating on GeneDx Holdings Corp. (NASDAQ:WGS) and maintained a price target of $153 on the company's stock following data presented at the ACMG Annual Meeting. The data indicated that the company's whole exome and genome testing notably reduces healthcare resource utilization and total healthcare costs. Analysts believe these findings strengthen GeneDx Holdings Corp. (NASDAQ:WGS)'s capabilities in the commercial and Medicaid coverage expansion. The firm remains bullish despite the company's shares witnessing a 9% decline on the same day, after its competitor Natera launched its Zenith genomics assay, which aims at offering improved detection of rare diseases. Separately, on February 24, 2026, BTIG analyst Mark Massaro maintained the firm's Buy rating on GeneDx Holdings Corp. (NASDAQ:WGS) but adjusted the price target from $200 to $170. The firm remains bullish follo
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- Previvor Edge Expands Platform to Deliver Personalized Clinical-Grade Cancer Risk Profiles and Interactive Prevention Plans [TheStreet.com]TheStreet.com
- Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage? [Yahoo! Finance]Yahoo! Finance
- Barrington Lowers PT on OPKO Health (OPK), Keeps a Buy [Yahoo! Finance]Yahoo! Finance
- “CNBC CURES: DEFYING RARE DISEASE” WITH BECKY QUICK TO PREMIERE ON THURSDAY, MARCH 19 AT 7PM ET [CNBC]CNBC
- GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
OPK
Earnings
- 2/26/26 - Beat
OPK
Analyst Actions
- 3/2/26 - Barrington Research
OPK
Sec Filings
- 3/20/26 - Form 4
- 3/20/26 - Form 4
- 3/20/26 - Form 3
- OPK's page on the SEC website